Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Thomas Weber , Bryan Williams , , et al Added: 1 year ago
If you missed the Symposium 'Cracking the Code of Uncontrolled Hypertension' at ESC 2024, the on-demand session is now available.Join Prof Thomas Weber (Klinikum Wels-Grieskirchen, Wels, AT), Prof John Flack (Southern Illinois University School of Medicine, Springfield, US), Prof Alta Schutte (University of New South Wales, Sydney, AU), and Prof Bryan Williams (University College London, London,… View more
Author(s): Thomas Weber , Erika SW Jones , Bryan Williams Added: 1 year ago
The long term clinical implications of uncontrolled hypertension are well documented, but almost half of those with hypertension remain inadequately treated. In this symposium, our panel of three leading hypertension experts, Prof Thomas Weber (Klinikum Wels-Grieskirchen, Wels, AT), Prof Bryan Williams (University College London, London, UK) and Prof Erika Jones (University of Cape Town, Cape… View more
Start date: Aug 30, 2024 End date: Aug 30, 2024
Radcliffe Medical Education is hosting a Satellite Symposium entitled 'Cracking the Code of Uncontrolled Hypertension' at ESC 2024, in London. Join us in the Prague room on Friday 30 August 2024 at 15:15.Add to your calendarOverviewThis symposium will delve into the complexities of uncontrolled hypertension, exploring its clinical impact, treatment barriers, and underlying drivers. It will… View more
Author(s): Harriette Van Spall , Luke Laffin Added: 1 year ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial… View more
Author(s): John Dodson , Harriette Van Spall Added: 7 months ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by BETTER-BP Principal Investigator Dr John Dodson (NYU Langone Health, New York, US) to present the findings of this AHA late-breaking trial (NCT04114669).The BETTER-BP (Behavioral Economics Trial to Enhance Regulation of Blood Pressure) is a phase II pragmatic randomized… View more
Author(s): Neha Pagidipati Added: 9 months ago
ESC Congress 2025 - KARDIA 3 finds that a single dose of zilebesiran 300mg reduced office systolic blood pressure at month three compared to placebo, informing the dose, design and patient population for the upcoming zilebesiran phase III Cardiovascular outcomes trial.Dr Neha Pagidipati (Duke University Medical Center, US) joins us to discuss findings from the KARDIA-3 trial, evaluating… View more
Author(s): Matthias Bossard Added: 7 months ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus… View more
Author(s): Nicolas Girerd Added: 1 year ago
ESC HF 25 - Outcomes from a study investigating liver stiffness measurement as a non-invasive method to assess central venous pressure showed immediate results at bedside obtained in >4 minutes, with the procedure easily performed by a trained nurse.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses a pilot validation study investigating liver stiffness as a non-invasive… View more